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 ABSTRACT: 
To understand the role of L-arginine depletion in impaired nitric oxide synthesis in 
disease, it is important to simultaneously quantify arginine, citrulline, and ornithine in the 
plasma. Because the three amino acids are endogenous analytes, true blank matrix for 
them is not available. It is necessary and valuable to compare the performance of 
different approaches due to lack of regulatory clarity for validation. A two-step sample 
preparation method using methanol as protein precipitation reagent was developed in 
this study is used for sample preparation. Because true blank matrix for endogenous 
analytes is not available, water as blank matrix, 1% BSA in PBS as blank matrix, 
surrogate analyte, and background subtraction were designed to establish successful 
quantification methods. Four methods to simultaneously quantify arginine, citrulline, and 
ornithine in human plasma using hydrophilic interaction liquid chromatography and 
electrospray tandem mass spectrometry were developed, validated, and compared. The 
developed two-step sample preparation method using methanol as protein precipitation 
reagent in this study needs less time and provides higher recovery comparing with other 
approaches. Three of the four methods, water as blank matrix, 1% BSA in PBS as blank 
matrix, and surrogate analyte, have been successful in fulfilling all the criteria, while 
background subtraction has failed. Results of the measured concentrations in 97 human 
plasma samples using the three methods show that the difference between any two 
methods or among the three methods presents 100% of samples with less than 20% for 
all the three amino acids and majority of them are under 10%. The developed two-step 
sample preparation method using methanol as protein precipitation reagent is simple 
and convenient. Three of the four methods are fully validated and the validation is 
 successful. The BSA functioned effectively as a blank matrix for these three amino 
acids, considering cost, data quality, matrix similarity, and practicality.
 1. Introduction 
 
This work measures L-arginine in plasma from patients with acute pulmonary 
embolism (PE). L-arginine is the primary substrate used by endothelial nitric oxide 
synthase to produce nitric oxide (NO) and L-citrulline. Nitric oxide then diffuses to the 
vascular smooth muscle, where it functions as the primary vasodilator of pulmonary 
vasculature; disease conditions that impair the normal steady-state delivery of NO 
secondarily allow for contraction of vascular smooth muscle. L-arginine can be depleted 
by either decreased intake or increased destruction, primarily by the action of circulating 
arginase-I (abundant in erythrocytes), which cleaves L-arginine to form ornithine and 
urea. Thus, the simultaneous measurement of L-arginine, citrulline and ornithine and 
their respective ratios, provides mechanistic insight into the cause of L-arginine 
depletion and subsequent NO lack. Prior work in animals and humans has found that 
acute pulmonary embolism (PE) causes hemolysis, leading to increased plasma 
arginase concentrations, with reduced L-arginine concentrations, leading to impaired 
NO synthesis and pulmonary vasopasm [1-4]. In the United States, approximately 
200,000 individuals are diagnosed with acute pulmonary embolism (PE) each year, 
resulting in substantial morbidity, primarily related to damage to the right ventricle [5]. 
Patients with severe tricuspid regurgitation, implying more severe PE and more 
hemolysis appear to be at the highest risk of acute L-arginine depletion, and persistent 
right ventricular dysfunction [6, 7]. 
Numerous quantitative methods have been developed and validated to 
determine a single amino acid of the three [8]. However, fewer methods have been 
 developed and validated for simultaneously quantification of any two of the three amino 
acids [9, 10]. Among various methods, hydrophilic interaction liquid chromatography 
(HILIC) columns are gaining popularity due to their simplicity, not requiring traditional 
derivatization steps or ion-pairing separations for amino acid separation. Currently, only 
one article has been reported to simultaneously quantify all the three amino acids in 
plasma or serum using a HILIC column [11]. However, the published method has not 
been fully validated.  
Because the three amino acids are endogenous analytes, true blank matrix for 
them is not available. Approaches using a surrogate matrix, background subtraction, or 
a surrogate analyte have been utilized to establish quantification methods for 
endogenous analytes in different projects [12-14]. It is necessary and valuable to 
compare these approaches due to lack of regulatory clarity for validation.  
In this study, several approaches have been utilized to establish successful 
quantification methods. Surrogate matrix is the first choice applied in many projects [15]. 
Water and BSA are the most commonly used surrogate matrix. When the plasma with 
endogenous analytes is used as blank matrix, two strategies have been applied: 
surrogate analyte approach by spiking of a stable isotope-labeled the analyte as a 
surrogate standard and background subtraction technique during data processing to 
handle the spiking of exogenous levels of the analyte. Due to the debate on which 
approach should be utilized and lack of regulatory clarity for validation of endogenous 
analytes, we compared four methods: water as blank matrix, 1% BSA in PBS as blank 
matrix, surrogate analyte, and background subtraction.  
 In summary, we report the development, validation, and comparison of four 
methods to simultaneously quantify arginine, citrulline, and ornithine in human clinical 
plasma using HILIC and tandem mass spectrometry (MS/MS). The established method 
is expected to be rapid and robust, enabling efficient analysis of large number of clinical 
plasma samples. 
 
2. Materials and methods 
 
2.1. Reagents 
 
L-arginine (99.0%, AR01), L-citrulline (98.0%, CI01), L-ornithine:HCl (99.0%, 
OR01), and BSA were purchased from Sigma-Aldrich (St. Louis, MO, USA). L-
arginine:HCl (guanido-15N2, 98.7%, AR21), L-arginine:HCl (13C6, 98.0%, AR61), L-
citrulline (5,5-D2, 99.3%, CI21) , L-citrulline (4,4,5,5-D4, 98.0%, CI41), L-ornithine:HCl 
(5,5-D2, 98.0%, OR21), and L-ornithine:HCl (3,3,4,4,5,5-D6, 98.9%, OR61) were 
obtained from Cambridge Isotope Laboratories (Tewksbury, MA). AR61, CI21, and 
OR21 were used as internal standards. AR21, CI41, and OR61 were used as surrogate 
analytes in the surrogate analyte approach. Ammonium formate was purchased from 
Santa Cruz Biotechnology (Dallas, TX). Phosphate Buffered Saline (PBS-1X) was 
obtained from Lonza (Allendale, NJ). LC-MS grade water (H2O), LC-MS grade 0.1% 
formic acid in acetonitrile (ACN), LC-MS grade ACN, and 0.1% formic acid in water 
(H2O) were purchased from Burdick & Jackson (Muskegon, MI, USA). Isopropyl alcohol 
and methanol (HPLC grade) were purchased from Fisher Scientific (Waltham, MA). The 
 details of the name, abbreviation, labelling, and chemical structure were listed in 
Supplemental Method 1. 
 
2.2. Patient samples 
 
This study was approved by the Indiana University Institutional Review Board 
(IRB # 1208009308). Patients were enrolled in an ongoing randomized, double-blind, 
placebo-controlled clinical trial (NCT01939301) to test the therapeutic efficacy of inhaled 
nitric oxide. Patients all had confirmed acute pulmonary embolism, diagnosed on the 
basis of contrast-enhanced computed tomography of the chest. All patients had 
evidence of right ventricular strain, usually with severe TR, and were treated with 
systemic heparin anticoagulation. Plasma was drawn by a qualified phlebotomist with 
care to avoid hemolysis. Blood for the current assay was additionally anticoagulated by 
addition of EDTA to a final concentration of 50 mmol/L. Within 30 min of blood draw, 
plasma samples were centrifuged at 4 °C and at 10,000 rcf for 20 min and aliquots of 
supernatants were stored at -80 °C until sample preparation for LC-MS/MS analysis. 
 
2.3. Sample preparation 
 
The details of the preparation of standards and quality control samples were 
described in Supplemental Method 2. Samples were prepared as follows: A 50 μL of 
each sample was spiked with 10 μL of 200 μM internal standard and incubated at room 
temperature for 10 min. The samples were extracted with 540 μL of methanol and 
 agitated in an Eppendorf Thermomixer at 1,400 rpm for 3 min followed by centrifugation 
at 14,000 rcf. 120 μL of supernatant was transferred to a vial and 80 μL of 5 mM 
ammonium formate were added into the vial. The samples were ready for analysis. 
 
2.4. Instrumentation 
 
A Dionex Ultimate 3000 UHPLC system (Sunnyvale, CA) consists of a pump, 
autosampler, column oven, and UV detector. A SCIEX 4000 QTRAP triple quadrupole 
mass spectrometer (Toronto, Canada) with a TurboIonSpray probe was used in positive 
ion mode. SCIEX Analyst 1.5 was used for data collection and SCIEX MutiQuant 3.0.1 
was used for peak integration and concentration calculation. 
 
2.5. Chromatographic conditions 
 
HPLC separation was performed on a Phenomenex Kinetex HILIC 100A column 
(4.6 × 100 mm, 2.6 μm) (Torrance, CA) at 30 °C. Mobile phase A was 5 mM ammonium 
formate with 0.1 % formic acid in water and B was ACN with 0.1 % formic acid. The 
gradient program was 0.0–0.5 min, 70 % B; 0.5–1.0 min, gradient to 40 % B; 1.0– 
3.5 min, 40 % B; 3.5–4.0 min, gradient to 70 % B; and 4.0–6.0 min, 70 % B. The flow 
rate was 0.6 mL/min during all separation steps and injection volume was 10 μL.  
 
2.6. Validation procedure 
 
 The validations were performed according to the Guidance for Industry: 
Bioanalytical Methods Validation issued by the U.S. Department of Health and Human 
Services, the Food and Drug Administration, the Center for Drug Evaluation and 
Research (CDER), and the Center for Veterinary Medicine (CVM) in May 2001. The 
details were described in Supplemental Method 3. 
 
3. Results and discussions 
 
3.1. Sample preparation 
 
Measuring plasma amino acids including arginine, citrulline, and ornithine have 
been reported with various sample preparation methods based on types of sample and 
analytical column, especially the analytical column selection. Currently, HILIC columns 
are gaining popularity due to their simplicity, not requiring traditional derivatization steps 
or ion-pairing separations for amino acid separation. To analyze one, two, or all of the 
three amino acids in plasma or serum in one injection using a HILIC column, several 
sample preparation approaches have been previously reported [10, 11, 16]. However, 
two issues were observed when the reported methods were followed during our method 
development. One of them was the choice of the reagent for protein precipitation. The 
other was the simplicity of sample preparation approaches. Acetonitrile, methanol, and 
isopropanol are the most commonly used protein precipitation reagents. When 
acetonitrile was applied initially in the development, it was found that the recovery of all 
three amino acids was low, especially for ornithine. Therefore, an investigation of 
 reagent type and volume was carried out to obtain better recovery for all the three 
amino acids. Arginine (AR21), citrulline (CI41), ornithine (OR61), and their internal 
standards (AR61, CI21, and OR21) were spiked into 50 μL of human plasma. Multiple 
volumes (two, three, four, five, seven, nine, and eleven times of 50 μL) of acetonitrile, 
methanol, and isopropanol were used for protein precipitation and the amino acid 
extraction. One fifth of the supernatant was transferred to a vial. Eighty μL of 5 mM 
ammonium formate were added into the vial, followed by adding certain amount of 
acetonitrile, methanol, or isopropanol to reach the final volume of 200 μL. Ten μL of 
each sample were injected for comparison. The results in Figure 1 indicates that 
reagent type is a greater factor than volume for the recovery. Around five times of the 
plasma volume, the performance for arginine is methanol > isopropanol > acetonitrile, 
for citrulline is methanol ≥ isopropanol > acetonitrile, and for ornithine is methanol > 
isopropanol ≥ acetonitrile. However, volume is a critical factor as well. The performance 
of acetonitrile dramatically decreases with the increase of its volume for all the three 
amino acids. The performance of isopropanol slightly decreases with the increase of its 
volume all the three amino acids. On the contrary, the performance of methanol stays 
stable with the increase of its volume all the three amino acids. Based on the 
performance and consideration of next steps in the sample preparation, 540 μL of 
methanol (about eleven times of the plasma volume) was chosen for protein 
precipitation and amino acid extraction. The extraction step was followed by a dilution 
step. Basically, the developed method is a two-step sample preparation approach. In 
numerous publications, dryness and resuspension steps are often involved, which 
 requires additional process. In comparison, the two-step sample preparation is simple 
and superior to other approaches.  
 
3.2. MS/MS detection 
 
Choosing product ions of the three amino acids has been diverse in literature. 
The product ions of arginine have been chosen as 43.0, 60.0, and 70.0 [11, 12, 17, 18], 
the product ions of citrulline have been chosen as 70.1, 113.0, and 159.1 [11, 12, 17, 
18], and the product ions of ornithine have been chosen as 70.0 and 116.1 [11, 17, 18]. 
Theoretically, multiple product ions are available for transition monitoring. As long as a 
transition passes the criteria in a full validation, especially the selectivity and LLOQ, the 
transition is acceptable. Transitions, retention times, and ionization source parameters 
for each analyte were listed in Supplemental Method 1. Representative chromatograms 
of the current LC-MS/MS analysis using the chosen transitions from a patient sample 
are shown in Figure 2. 
 
3.3. Calibration curve and linearity 
 
The assay validation has been designed to carry out using four methods: water 
as blank matrix, 1% BSA in PBS as blank matrix, surrogate analyte, and background 
subtraction.  The calibration curves from three consecutive batches using water as 
blank matrix showed an overall accuracy of 98.3–100.8% with RSD of less than 3.7% 
for arginine, 99.2–101.0% with RSD of less than 2.9% for citrulline, and 97.3–102.2% 
 with RSD of less than 2.5% for ornithine. The detailed results are shown in 
Supplemental Table 1. The calibration curves from three consecutive batches using 
BSA as blank matrix showed an overall accuracy of 95.3–104.8% with RSD of less than 
2.6% for arginine, 98.7–102.6% with RSD of less than 4.1% for citrulline, and 97.3–
103.1% with RSD of less than 3.8% for ornithine. The detailed results are shown in 
Table 1 and Supplemental Table 2. The calibration curves from three consecutive 
batches using surrogate analytes showed an overall accuracy of 96.8–104.1% with 
RSD of less than 3.9% for arginine, 94.5–107.5% with RSD of less than 6.2% for 
citrulline, and 98.6–103.3% with RSD of less than 3.1% for ornithine. The detailed 
results are shown in Supplemental Table 3. The linear ranges of the three amino acids 
using the first three methods are 4–200 μM, covering the reported clinical concentration 
levels [11].  
The last method, background subtraction, encountered a great challenge. The 
endogenous levels of arginine, citrulline, and ornithine in the human plasma serving as 
blank matrix are 154.4, 17.0, and 63.1 μM, respectively. Fifteen percent of the 
endogenous levels are 23.2, 2.6, and 9.5 μM. Spiking any amount of standards below 
the 15% of the endogenous level may not even produce any significant peak area 
changes, since the requirement of precision is RSD≤20.0% at LLOQ and ≤15.0% at any 
other concentration level. Results show that the linear ranges of arginine, citrulline, and 
ornithine using the background subtraction method are 25–200, 4–200, and 10–200 μM, 
respectively. Comparing to the other three methods, the background subtraction method 
exhibits a limited linear range. The calibration curves from three consecutive batches 
using the background subtraction showed an overall accuracy of 98.3–103.6% with 
 RSD of less than 6.1% for arginine, 95.0–105.0% with RSD of less than 4.5% for 
citrulline, and 97.2–101.8% with RSD of less than 6.9% for ornithine. The detailed 
results are shown in Supplemental Table 4. 
 
3.4. Precision and accuracy 
 
The intra- and inter-assay precision and accuracy from the three consecutive 
batches using water as blank matrix are shown in Supplemental Table 5. The intra-
assay accuracy is 88.8–99.3% with RSD of 1.1–3.3% for arginine, 92.5–101.5% with 
RSD of 0.6–2.9% for citrulline, and 91.9–102.1% with RSD of 1.2–3.5% for ornithine. 
The inter-assay accuracy is 90.3–95.3% with RSD of 1.8–4.3% for arginine, 95.3–
99.8% with RSD of 1.6–3.8% for citrulline, and 94.5–98.6% with RSD of 2.0–3.8% for 
ornithine. The intra- and inter-assay precision and accuracy from the three consecutive 
batches using BSA as blank matrix are shown in Table 2 and Supplemental Table 6. 
The intra-assay accuracy is 90.5–108.0% with RSD of 1.3–3.2% for arginine, 95.7–
105.9% with RSD of 1.1–4.4% for citrulline, and 94.7–104.1% with RSD of 1.1–2.7% for 
ornithine. The inter-assay accuracy is 90.3–95.3% with RSD of 1.8–4.3% for arginine, 
96.6–103.8% with RSD of 1.4–5.2% for citrulline, and 95.1–102.8% with RSD of 1.8–
3.0% for ornithine. The intra- and inter-assay precision and accuracy from the three 
consecutive batches using surrogate analytes are shown in Supplemental Table 7. The 
intra-assay accuracy is 87.2–101.8% with RSD of 1.1–3.4% for arginine, 89.9–106.9% 
with RSD of 1.0–5.0% for citrulline, and 90.9–105.0% with RSD of 0.8–3.4% for 
ornithine. The inter-assay accuracy is 88.2–99.9% with RSD of 2.2–2.9% for arginine, 
 90.3–103.8% with RSD of 2.0–4.2% for citrulline, and 91.4–102.4% with RSD of 1.6–
3.0% for ornithine. 
When the background subtraction method was applied, all QC levels including 
LLOQ of citrulline fulfilled the requirement, but only high and mid QCs of arginine and 
ornithine met the criteria. The detailed results are shown in Supplemental Table 8. The 
precision and accuracy from three consecutive batches show an intra-assay accuracy of 
91.1–101.7% with RSD of 4.0–10.4% for arginine, 91.3–105.8% with RSD of less than 
1.6–14.0% for citrulline, and 88.8–99.4% with RSD of 2.3–6.0% for ornithine. The inter-
assay accuracy is 92.4–101.3% with RSD of 4.7–8.4% for arginine, 97.4–100.3% with 
RSD of 2.2–12.4% for citrulline, and 94.8–96.1% with RSD of 4.2–6.3% for ornithine.  
The precision and accuracy of dilution QCs are shown in Supplemental Tables 
9–12. An accuracy of 93.5% with RSD of 1.7% for arginine, 98.9% with RSD of 0.5% for 
citrulline, and 101.4% with RSD of 0.7% for ornithine were achieved when water was 
used as blank matrix. An accuracy of 91.9% with RSD of 0.9% for arginine, 96.7% with 
RSD of 1.5% for citrulline, and 98.6% with RSD of 1.3% for ornithine were achieved 
when BSA was used as blank matrix. An accuracy of 86.5% with RSD of 1.1% for 
arginine, 86.4% with RSD of 1.2% for citrulline, and 86.4% with RSD of 1.2% for 
ornithine were achieved when the surrogate analytes were applied. An accuracy of 
90.3% with RSD of 5.4% for arginine, 98.9% with RSD of 0.7% for citrulline, and 99.8% 
with RSD of 3.3% for ornithine were achieved when the background subtraction was 
utilized. 
 
3.5. Selectivity  
  
Using the first three methods, all the tested six lots of blank matrix samples 
showed that interference peaks at the retention time of interest either did not exist or 
satisfied the criteria. Selectivity LLOQs using water as blank matrix obtained an 
accuracy of 96.0% with an RSD of 2.5% for arginine, 102.0% with an RSD of 1.8% for 
citrulline, and 106.2% with an RSD of 4.9% for ornithine. Selectivity LLOQs using BSA 
as blank matrix obtained an accuracy of 105.6% with an RSD of 5.5% for arginine, 
108.7% with an RSD of 6.3% for citrulline, and 106.2% with an RSD of 4.9% for 
ornithine. Selectivity LLOQs using surrogate analytes obtained an accuracy of 90.0% 
with an RSD of 3.6% for arginine, 96.2% with an RSD of 4.1% for citrulline, and 101.9% 
with an RSD of 2.4% for ornithine. The detailed results are shown in Supplemental 
Table 13–15. When the background subtraction method was applied, the selectivity 
assessment was not applied, because the blank samples had high endogenous levels. 
 
3.6. Matrix effect 
 
The detailed matrix effect results are shown in Supplemental Table 16–18. Matrix 
effect LOQs using water as blank matrix exhibit 0.9% for arginine, 0.5% for the internal 
standard of arginine, 1.4% for citrulline, 1.4% for the internal standard of citrulline, 2.0% 
for ornithine, and 2.0% for the internal standard of ornithine. Matrix effect LOQs using 
BSA as blank matrix exhibit 7.7% for arginine, 6.2% for the internal standard of arginine, 
–53.9% for citrulline, –53.8% for the internal standard of citrulline, 7.1% for ornithine, 
and 2.7% for the internal standard of ornithine. Matrix effect LOQs using surrogate 
 analytes exhibit –24.3% for arginine, –25.3% for the internal standard of arginine, –
58.3% for citrulline, –58.4% for the internal standard of citrulline, –9.9% for ornithine, 
and –10.1% for the internal standard of ornithine. All six lots of matrix have showed 
similar matrix effect for both analytes and their corresponding internal standards. When 
the background subtraction method was applied, the matrix effect evaluation was not 
applied, because the blank samples had high endogenous levels. 
 
3.7. Recovery 
 
Overall recoveries from low, mid, and high QCs using water as blank matrix were 
93.1% for arginine, 95.4% for the internal standard of arginine, 93.8% for citrulline, 
91.2% for the internal standard of citrulline, 93.1% for ornithine, and 91.4% for the 
internal standard of ornithine. The detailed results are shown in Supplemental Table 19. 
Overall recoveries from low, mid, and high QCs using BSA as blank matrix were 85.0% 
for arginine, 91.5% for the internal standard of arginine, 88.0% for citrulline, 93.8% for 
the internal standard of citrulline, 83.3% for ornithine, and 90.4% for the internal 
standard of ornithine. The detailed results are shown in Table 3. Overall recoveries from 
low, mid, and high QCs using surrogate analytes were 74.7% for arginine, 78.6% for the 
internal standard of arginine, 85.8% for citrulline, 91.5% for the internal standard of 
citrulline, 78.5% for ornithine, and 83.5% for the internal standard of ornithine. The 
detailed results are shown in Supplemental Table 20. The results indicate that 
consistent recoveries at all three QC levels of all analytes and their internal standard 
have been achieved. When the background subtraction method was applied, the 
 selectivity assessment was not applied, because of the high endogenous levels in blank 
samples. 
 
3.8. Stability 
 
The stability results of the analytes in BSA under different conditions are shown 
in Table 4. The accuracy and precision of three freeze/thaw cycles, 48h room 
temperature storage, and 55 days storage at −60 to −80 ◦C fit the ± 15% criteria. 
Additionally, stability of 72h processed-sample reinjection, 56 days intermediate 
standard solutions, and 57 days stock standard solutions stored at 2–8 ◦C were 
examined. All results demonstrate that the analytes are stable. The stability results of 
the analytes in water and human plasma under different conditions are shown in 
Supplemental Tables 21 and 22. 
 
3.9. Comparison of the four methods  
 
The four methods, water as blank matrix, 1% BSA in PBS as blank matrix, 
surrogate analyte, and background subtraction, have been fully validated. The first three 
methods have been successful in fulfilling all the criteria, while the last one has failed in 
LLOQs, LOQs, and low concentrations of the calibration curves. The reason is that the 
blank samples have high endogenous levels. This is one of the two significant issues in 
the application of background subtraction. It is extremely difficult to obtain a plasma 
sample that contains the lowest levels of the endogenous analyte. Assuming such a 
 sample as blank matrix is available, any other samples whose endogenous level near 
the blank matrix sample still face the challenge of accurate quantification, because its 
LLOQ may not cover these samples. The other significant issue in the application of 
background subtraction is data processing. Currently, MultiQuant is able to calculate the 
exogenous level of a spiked analyte by subtracting the endogenous level of the analyte 
of choice, but considering the endogenous level of the analyte as zero. It works for 
validation, since exogenous spiking is applied. However, it is not able to obtain the real 
endogenous level of analytes, because the endogenous level in every sample is 
subtracted by the endogenous level in the matrix severing as a blank sample, showing 
that any assay sample having an endogenous level equal or less than the endogenous 
level in the matrix will be assigned zero or a negative value after the calculation. Some 
software may be able to process the data differently without zeroing the matrix level. 
However, these software are often limited with certain mass spectrometers. Crossing 
different platforms or data formats commonly is not available for regular users. 
Therefore, background subtraction is the last choice of methods for analyzing 
endogenous analytes. 
On the contrary, the first three methods are easily practicable without considering 
the two issues described above. However, they are still different from each other with 
advantages and disadvantages. To compare them, cost, data quality, and matrix 
similarity are considered. Because surrogate analyte method requires additional stable 
isotope-labeled standards, it is more expensive than the other two methods. When the 
surrogate analyte method is applied, three transitions need to be monitored rather than 
two transitions to monitor in the other two methods. Therefore, less scan time is spent 
 on each transition, leading to less accurate peak intensity, especially for low abundance 
analytes. When multiple analytes are under detection at the same retention time, an 
additional transition in the three transitions may become a burden. For matrix similarity, 
the surrogate analyte method has the identical matrix as endogenous analyte does, 
water is the most unlike matrix, and BSA is in the middle. Generally speaking, BSA is 
the number one choice, water is the second choice, and the surrogate analyte method 
is the last one based on the three factors. If cost is not a burden and a high 
performance mass spectrometer is available with faster scan speed, the surrogate 
analyte method seems to be a good choice. However, researchers have to examine 
whether same amount of analyte and surrogate analyte have the same signal response 
on a mass spectrometer. Unlike exogenous analysis that uses an identical matrix and 
analyte, endogenous analysis has to use either a surrogate matrix or a surrogate 
analyte. Therefore, there is no universal rule on whether surrogate matrix or surrogate 
analyte should be applied. Researchers should consider the cost of labelled analytes, 
the performance of a mass spectrometer, and the type of matrix comprehensively. A 
comparison of surrogate matrix and surrogate analyte methods for quantitation of 
endogenous biomolecules concludes that both assays are well within tolerances 
prescribed by regulatory guidance for validation, the surrogate analyte approach allows 
for facile method development, and the surrogate matrix method has the long-term 
advantage of simplified sample analysis [15]. Another comparison shows that the 
surrogate analyte in authentic matrix approach performed as well as the authentic 
analyte in surrogate matrix approach, indicating that the surrogate analyte approach is 
 not required for the accurate quantification of endogenous compounds in complex 
samples [19]. 
To evaluation the four methods, four sets of calibration curve with QCs and 97 
patient samples were analyzed using the four validated methods. The background 
subtraction approach has failed in the LOQs, calibration curve, and concentration 
calculation of patient samples. The first three methods have been successful in fulfilling 
all the criteria. The comparison between any two of the methods was carried out using 
the equation for sample reanalysis published in the EMEA/CHMP/EWP guideline on 
bioanalytical method validation, i.e. %difference equals the absolute different value of 
two methods divided by the mean value of the two methods and multiplied by 100. A 
RSD value of the three methods a calculated. The detailed comparison are shown in 
Figure 3. If the percent difference between the initial concentration and the 
concentration measured during the repeat analysis are not greater than 20% of their 
mean for at least 67% of the repeats, the EMEA guide considers the reproducibility of 
an analysis acceptable. The difference between any two methods or among the three 
methods presents 100% of samples with less than 20% for all the three amino acids. 
Mainly, the difference is under 10%. According the EMEA criteria, the measured 
concentrations have no difference between or among the three methods. The BSA 
functioned effectively as a blank matrix for these three amino acids, considering cost, 
data quality, matrix similarity, and practicality. 
 
4. Conclusion 
 
 The developed two-step sample preparation method using methanol as protein 
precipitation reagent in this study is simple and superior to other approaches. Four LC-
MS/MS methods have been developed for simultaneous determination of arginine, 
citrulline, and ornithine in human plasma. The four methods have been fully validated 
and compared. Three of them have been confirmed rapid and robust. The three 
methods have been directly applied to patient sample analysis. The results show that 
the measured concentrations have no difference between or among the three methods. 
When experimental data excluding its use as a blank matrix is absent, the BSA 
approach is the best choice among the four methods for an assay application, 
considering cost, data quality, matrix similarity, and practicality. 
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 Figure Legends 
 
Figure 1. Comparing the effect of reagent type and volume on the recoveries of all the 
three amino acids. Multiple volumes (2, 3, 4, 5, 7, 9, and 11 times of 50 μL) of 
acetonitrile (ACN), isopropanol (IPA), and methanol (MeOH) were used to precipitate 
proteins in 50 μL of plasma spiked with arginine (AR21), citrulline (CI41), ornithine 
(OR61), and their internal standards (AR61, CI21, and OR21). It shows that reagent 
type is a greater factor than volume for the recovery and volume is a critical factor as 
well. The performance of methanol is the best for all the three amino acids. 
 
Figure 2. Representative chromatograms of the current LC-MS/MS analysis using the 
chosen transitions from a patient sample spike with mid QC and IS. Peak intensity and 
elution times (min) are shown for authentic analytes (AR01, CI01, and OR01), surrogate 
analytes (AR21, CI41, and OR61), and internal standards (AR61, CI21, and OR21). 
 
Figure 3. Comparing the performance of the three four methods: water as blank matrix, 
1% BSA in PBS as blank matrix, and surrogate analyte. Percentage difference between 
any two of the methods and RSD value among the three methods were carried out. The 
results show that he difference between any two methods or among the three methods 
presents 100% of samples with less than 20% for all the three amino acids. Mainly, the 
difference is under 10%. Therefore, the measured concentrations in 97 human plasma 
samples are considered not different between or among the three methods. 
 Table 
Table 1. Precisions and accuracies of calibration standards of OR01 in 1% BSA from 
three validation batches.  
Analysis group Theoretical concentration (µM)         
  4.0 5.0 10.0 25.0 75.0 100.0 150.0 200.0 
  Measured concentration (µM)          
001 4.1 4.9 9.8 25.5 76.0 96.3 159.5 192.9 
002 3.9 4.8 10.1 25.1 79.5 101.1 150.6 193.9 
003 4.2 4.9 10.0 24.2 76.2 98.5 153.7 197.3 
                  
n 3 3 3 3 3 3 3 3 
Mean 4.1 4.9 10.0 24.9 77.2 98.6 154.6 194.7 
RSD (%) 3.8 1.2 1.5 2.7 2.5 2.4 2.9 1.2 
Accuracy (%) 101.7 97.3 99.7 99.7 103.0 98.6 103.1 97.4 
 
 
 
 Table 2. Precisions and accuracies of quality control samples for OR01 in 1% BSA from 
three validation batches.  
Analysis 
group 
Statistics Theoretical concentration (µM) 
  4.0 7.5 50.0 125.0 
  n 6 6 6 6 
001 Intra-assay mean 4.1 7.6 47.7 130.1 
  RSD (%) 1.6 1.9 1.1 1.6 
  Accuracy (%) 102.5 101.1 95.4 104.1 
            
  n 6 6 6 6 
002 Intra-assay mean 4.1 7.3 47.4 127 
  RSD (%) 1.6 2.2 1.2 2.6 
  Accuracy (%) 102.4 97.2 94.7 101.6 
            
  n 6 6 6 6 
003 Intra-assay mean 4.1 7.6 47.6 126 
  RSD (%) 2.0 2.7 1.8 1.3 
  Accuracy (%) 103.5 102.0 95.2 100.8 
            
  n 18 18 18 18 
Overall Inter-assay mean 4.1 7.5 47.5 127.7 
  RSD (%) 1.8 3.0 1.4 2.3 
  Accuracy (%) 102.8 100.0 95.1 102.2 
 
 
 
 
 
 
 
 
 Table 3. Recoveries at low, mid and high QC levels for AR01 (IS, AR61), CI01 (IS, 
CI21), and OR01 (IS, OR21) in 1% BSA.  
QC levels  Statistics  AR01 AR61 CI01 CI21 OR01 OR21 
                
Low RSD (%)a 4.7/2.2 4.2/1.2 7.3/12.9 6.3/10.2 3.9/3.4 3.0/0.3 
  Recovery (%)  83.0 87.1 90.6 91.1 85.1 87.9 
                
Mid RSD (%)a 6.1/0.7 6.6/0.6 8.7/5.7 8.8/5.9 2.9/1.7 3.7/1.3 
  Recovery (%)  84.5 94.1 86.0 96.6 80.8 91.5 
                
High RSD (%)a 4.3/6.1 4.5/6.7 11.8/12.9 12.1/11.5 2.8/5.0 3.6/4.5 
  Recovery (%)  87.3 93.4 87.3 93.7 84.1 92.0 
                
Overall  Recovery (%)  85.0 91.5 88.0 93.8 83.3 90.4 
a RSD: RSD of six replicates of extracted QC samples/RSD of three replicates of 
recovery samples. 
 
 
 
 
 
 
 
 
 
 Table 4. Stability of AR01, CI01, and OR01 at low, mid and high QC levels in 1% BSA 
under different conditions.  
QC levels  Statistics  AR01 CI01 OR01 
          
Three freeze/thaw matrix stability       
  n 6 6 6 
Low RSD (%) 2.0 2.1 2.3 
  Accuracy (%)  99.1 102.0 103.6 
          
  n 6 6 6 
Mid RSD (%) 1.6 1.9 1.5 
  Accuracy (%)  95.1 97.6 97.2 
          
  n 6 6 6 
High RSD (%) 2.5 1.3 1.6 
  Accuracy (%)  98.2 103.2 102.4 
          
48 h room temperature matrix stability       
  n 6 6 6 
Low RSD (%) 0.7 2.8 1.4 
  Accuracy (%)  97.8 102.2 100.9 
          
  n 6 6 6 
Mid RSD (%) 1.7 1.5 1.1 
  Accuracy (%)  95.5 97.9 95.3 
          
  n 6 6 6 
High RSD (%) 1.3 0.6 1.6 
  Accuracy (%)  96.7 100.9 100.0 
          
55 days −60 to −80 ◦C matrix stability       
  n 6 6 6 
Low RSD (%) 1.9 11.3 3.9 
  Accuracy (%)  95.3 98.4 99.3 
          
  n 6 6 6 
Mid RSD (%) 2.0 3.0 1.2 
  Accuracy (%)  97.5 99.9 100.4 
          
  n 6 6 6 
 High RSD (%) 3.4 2.8 2.8 
  Accuracy (%)  98.2 102.8 102.9 
 
 
 
 
 
 
 
 
 
 
 
 
